GlassScriptPhysician profile
John W Lacount
NPI 1649250747
$4,272.46
in general payments reported to CMS, 2019-2025
22 companies · $792 in 2025
The $792 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $93.98 · 2021: $273 · 2022: $608 · 2023: $808 · 2024: $1,385 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,101.28 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $668.27 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $416.81 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $269.19 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $240.68 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Cranial Technologies, INC | $211.93 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $195.20 | 2020-2025 | Bexsero |
| Alk-Abello, INC | $186.72 | 2023-2025 | Ragwitek, Grastek, Odactra |
| Neos Therapeutics, LP | $167.32 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Collegium Pharmaceutical, INC. | $166.19 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $132.91 | 2019-2022 | |
| Pfizer INC. | $126.85 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $122.79 | 2024-2025 | |
| Sobi, INC | $67.92 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $45.56 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $36.89 | 2025 | Ycanth |
| Sanofi Pasteur INC. | $31.26 | 2023-2024 | |
| Rhodes Pharmaceuticals L.P. | $27.72 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.57 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.65 | 2024 | Relexxii |
| Mylan Pharmaceuticals INC. | $13.01 | 2019 | |
| Shire North American Group INC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lacount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.